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ABSTRACT 
 
BACKGROUND 
 
Locally advanced breast cancer (LABC) occurs relatively infrequently and poses a 
significant clinical challenge. Even with combined-modality therapy and the use of 
novel drugs, long-term disease-free survival is approximately 50%-70%88, indicating 
that the optimal therapeutic approach for these patients has not yet been reached. Neo-
adjuvant systemic therapy integrated into a multimodality program is the established 
treatment in LABC. Pathological response to neoadjuvant chemotherapy directly 
correlates with disease free survival and hence this study was undertaken. 
AIM 
 To assess the pathological response of neoadjuvant chemotherapy in locally 
advanced breast carcinoma. 
 
MATERIALS AND METHODS 
 
STUDY CENTRE: Institute of General Surgery , Madras Medical College and Rajiv 
Gandhi Government General Hospital , Chennai 
 
DURATION OF STUDY:  May 2017- September 2018 
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STUDY DESIGN: Observational study 
 
SAMPLE SIZE: 30 
 
INCLUSION CRITERIA:  
 
 Age > 18 years 
 
 Locally advanced carcinoma 
 
 Willing for follow up  
 
 
EXCLUSION CRITERIA 
 
 Prior Breast Surgery  
 
 Prior radiotherapy to breast 
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 Metastatic disease  
 
ETHICS CLEARANCE: Yes 
METHODOLOGY  
 Patients aged >18 years presenting with malignant breast lump were evaluated.  
 
 Diagnosis confirmed by core needle biopsy and grade and hormonal status 
assessed and metastatic work up done.  
 
 Thirty patients who fulfilled the inclusion criteria were chosen and were sent 
for neoadjuvant chemotherapy.(FAC OR FAC+PACLITAXEL REGIMEN)  
 
 Patients were followed up and response of tumor assessed clinically and 
modified radical mastectomy was done. 
 
 
 Specimen was analyzed for pathological response and observations made. 
 
RESULTS 
 
Majority of the population belonged to the age group of 50-60 (33%). Of the 30 
patients having locally advanced carcinoma  73% belonged to stage stage IIIA and 
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27% belonged to stage IIIB.Almost half of the patients were ER positive, PR positive 
and HER2 negative and 23% of the patients were triple positive.Triple negative and 
HER 2 positive patients were of equal distribution (17%).Percentage of ER and PR 
positive tumors were 67% each.Percentage of HER2 positive tumors were 
40%.Postoperative assessment of specimen was done and pathological response 
graded according to Chevalier classification. 
 53% were of grade 4 
 30% were of grade 3 
 13%were of grade 2 
 3% was of grade 1 
Only 17% of patient population showed pathological response to NACT 83% were 
non responders which could possibly be explained due to higher ER positivity and 
lower response. 
CONCLUSION 
Identifying which tumors are most likely to respond to specific agents and 
regimens could significantly improve prognosis. Clinical management of LABC 
could be modified based on advances in our knowledge of cancer biology and 
genomic profiling to a highly effective individualized approach 
  
Keywords: LABC, neoadjuvant chemotherapy,pathological response 
 
8 
 
 
 
TABLE OF CONTENTS 
 
 
S.No. Topic Page No. 
1 Introduction 9 
2 Aims And Objectives 12 
3 Review Of Literature 13 
4 Methodology 42 
5 Results 45 
6 Discussion 52 
7 Conclusion 55 
8 References 57 
9 Annexure 73 
10 Plagiarism certificate 80 
 
  
9 
 
 
INTRODUCTION 
 
Globally, carcinoma breast is one of the commonest malignancies in women and it is 
the second most common cause of cancer related death in females. In India , it is the 
second most common cancer, first being carcinoma cervix. According to National 
Cancer Registry Programme, breast cancer accounts for about > 30% of all cancers in 
Indian women where urban areas hold the highest incidence.1,2 
 
Locally advanced breast carcinoma refers to a diverse and heterogeneous group of 
breast cancer and represents about 10 – 20% of all breast cancers in the developed 
world 5, while in India this group comprises about 60% of cases.  
 
Globally, definition of Locally Advanced Breast Carcinoma is notuniform in various 
centres. Recent guidelines of U.S National Comprehensive Cancer Network classified 
locally advanced breast cancer as AJCC stage III. It includes: 
 
 Tumour > 5 cms with regional lymph node involvement ( N1-N3) 
 Tumours of any size with chest wall or skin involvement or both, regardless of 
regional lymph node involvement. 
 Presence of regional lymph node involvement irrespective of tumour size 
 Fixed / matted axillary lymph nodes 
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
 Infraclavicular / supraclavicular lymph nodes 
 Internal mammary lymph nodes 
 
(Note: In the 7th edition of AJCC – 2010, ipsilateral supraclavicular lymph node 
involvement was reclassified as regional lymph node involvement) 
 
Based on probability of getting histologically negative margins after initial surgery, 
locally advanced breast carcinomas are classified as operable and inoperable. 
According to NCCN guidelines -2017: 
 
1) Operable LABC : T2N1M0, T3 N0-1 M0 
2) Inoperable LABC : Stage IIIA except T3N1M0 , Stage IIIB, Stage IIIC 
 
(Note : NCCN Panel accepts the definition of negative margin as "No ink on the 
tumour," - 2014 Society of Surgical Oncology-American Society for Radiation 
Oncology Consensus Guidelines on Margins) 
 
In the past, inflammatory breast carcinoma was considered as a subtype of locally 
advanced breast carcinoma.6 On comparison with noninflammatory forms of locally 
advanced breast carcinoma, inflammatory breast cancer carries a poor prognosis. So 
separate guidelines were formed for its management. 
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Until the middle of last century, primary treatment of LABC was radical mastectomy. 
This did not change until Stout et al ,4,5identified the markers of poor outcome such as 
skin ulceration, oedema, tumour fixation etc. The Oxford review stated that the use of 
systemic therapy to treat micro metastasis, significantly reduces the risk of recurrence 
and death. 
 
Neoadjuvant therapy, a newer modality of treatment evolved during the last three 
decades, is being practised all over the world for down staging technically inoperable 
locally advanced breast cancer prior to surgery. The literal meaning of the term 
neoadjuvant refers to a “new” ( Greek ) treatment added to “ assist” ( Latin ) a primary 
treatment. The biological rationale for neoadjuvant therapy for breast carcinoma is 
based on the observation of accelerated metastatic growth following tumour resection 
in animal models. 
 
Neoadjuvant chemotherapy is established as standard treatment for LABC with 
varying pathological response rate.7 There is significant association between the 
extent of pathological response and longterm outcome in terms of disease free 
survival- DFS and overall survival-OS8 
 
 
This study was conducted to assess the pathological response of neoadjuvant in locally 
advanced breast carcinoma. 
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AIMS 
 To assess the response to neoadjuvant chemotherapy in cases of locally 
advanced breast carcinoma 
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REVIEW OF LITERATURE 
 
According to Globocan 2012, India along with United States and China collectively 
accounts for almost one third of the global breast cancer burden. India is facing 
challenging situation due to 11.54% increases in incidence and 13.82% increase in 
mortality due to breast cancer during 2008–2012.9,10 The main reasons for this 
observed hike in mortality is due to lack of inadequate breast cancer screening, 
diagnosis of disease at advanced stage and unavailability of appropriate medical 
facilities. Breast cancer attains top rank even in individual registries (Mumbai, 
Bangalore, Chennai, New Delhi and Dibrugarh) in females during the period of 2012–
2014. 
 
Factors as marital status, location (urban/rural), BMI, breast feeding, waist to hip 
ratio, low parity, obesity, alcohol consumption, tobacco chewing, smoking, lack of 
exercise, diet, environmental factors were major risk factors in India leading to 
increasing incidence cancer; however, the reason for high incidence of breast cancer 
in younger women are not well known. Delayed disease presentation due to illiteracy, 
lack of awareness, financial constrains in some regions of India leads to late diagnosis, 
which in turn increases mortality rate. Lack of organized breast cancer screening 
program, paucity of diagnostic aids, and general indifference toward the health of 
females in the predominantly patriarchal Indian society are also the drawbacks leading 
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to increased breast cancer incidence. Hence majority of patients here are still treated at 
locally advanced and metastatic stages.11 
 
LOCALLY ADVANCED BREAST CANCER  
 
Locally advanced breast cancer is a subset of breast cancer characterized by the most 
advanced breast tumours in the absence of distant metastasis. The need to identify labc 
as a separate group of breast cancers arose in view of the high associated rate of 
locoregional and systemic failure (in the absence of distant metastasis at presentation) 
despite the best efforts of surgeons to remove locoregional spread of the tumour in its 
entirety.12 
 
The earliest therapy for locally advanced breast carcinoma was radical mastectomy13. 
However patients with supraclavicular lymphadenopathy, oedema of arm, satellite 
skin nodules, and extensive breast oedema were all found to develop recurrences and 
these signs were considered markers of inoperable disease. Patients who were treated 
with primary radiotherapy also had a high risk for disease recurrence and death, as 
well as the complications of chest wall fibrosis, brachial plexopathy, lypmhedema, 
skin ulceration, and skin necrosis14.The first reports of the use of systemic 
chemotherapy for locally advanced disease was published in the 1970s.15Since then, 
the use of systemic chemotherapy has become standard and has substantially 
improved the prognosis of locally advanced breast carcinoma. 
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Patients with locally advanced breast cancer are at high risk of relapse and death as a 
result of metastatic disease. The long-term outcome of these patients is rarely 
reported. The National Cancer Database statistics show that patients with stage III 
disease who underwent modified radical mastectomy and both radiation and systemic 
treatment have a 3-year relative survival rate of 68%, a 5-year relative survival rate of 
50%, and a 10-year relative survival rate of 36%.16 The National Cancer Institute 
investigated the outcome of 61 patients with noninflammatory stage III breast cancer 
who received neoadjuvant chemotherapy and hormonal adjuvant treatment. Patients 
who had a complete response received definitive radiotherapy to the breast and axilla 
and patients with residual disease underwent mastectomy, lymph node dissection, and 
radiotherapy. The 15-year overall survival was 50% for stage IIIA and 23% for stage 
IIIB breast cancer.17 
 
 In a series of 831 patients with locally advanced breast cancer treated at the M.D. 
Anderson Cancer Center between 1974 and 1991 in clinical trials with neoadjuvant 
anthracyclinebased chemotherapy regimens followed by surgery or radiation therapy, 
the median follow-up duration was 69.9 months. Patients with locally advanced breast 
cancer included 490 (59%) with inoperable disease at diagnosis. The 5-year 
recurrence-free and overall survival rates were 56% and 63%, respectively18. Locally 
advanced breast cancer comprises a heterogeneous group of tumors, with marked 
variations in outcome that depend on the TNM stage and the molecular characteristics 
of the tumor. It is anticipated that the introduction of highly effective systemic agents 
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such as taxanes, trastuzumab, lapatinib, and the aromatase inhibitors will lead to an 
improvement in the survival of these patients. 
 
 
DIAGNOSIS 
 
Like all breast cancers, locally advanced breast cancer can be detected during physical 
examination or with mammography. Because these tumors are large and most are 
easily palpable, diagnosis can be established by a core needle biopsy. Estrogen 
receptor (ER) and progesterone receptor (PR) status, nuclear grade, and presence of 
HER2/neu, p53, and Ki67 can all be determined on the basis of histologic examination 
of tissue obtained by core biopsy. It is important that radiopaque clips be placed at the 
time of biopsy of suspicious areas to provide localization of disease for future surgical 
planning, especially if the patient may be a candidate for neoadjuvant chemotherapy.  
 
Once invasive breast cancer is diagnosed, the patient should undergo a full staging 
evaluation to determine the extent of disease. Diagnostic bilateral mammograms are 
essential to determine whether any other clinically occult lesions are present in the 
same or contralateral breast. Ultrasonography is not always necessary but can be 
useful to measure tumor size, especially in women with dense breasts, and to 
determine whether axillary, infraclavicular, or supraclavicular nodes are involved. 
Breast magnetic resonance imaging (MRI) in addition to mammography or 
mammography and ultrasound has been shown to more accurately delineate the extent 
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of local disease and identify patients for whom breast-conserving surgery would be 
contraindicated19.The routine use of MRI for the staging of patients with breast cancer 
has been limited by the lack of proven benefit that it reduces local recurrences and 
mortality20. 
 
After the extent of local-regional disease has been established, patients should 
undergo evaluation for systemic disease. All patients should undergo a thorough 
physical examination. Recommended staging studies are laboratory evaluation, 
including complete blood count, platelets, liver function tests, alkaline phosphatase, 
and chest radiography. Patients in whom any abnormalities are detected on laboratory 
evaluation or suggested by history and physical examination should undergo 
abdominal imaging with either ultrasonography or computed tomography (CT) and 
nuclear medicine bone scan. Other tests, such as CT of the chest or brain and MRI 
scans, should be performed if indicated on the basis of physical examination or by the 
presence of symptoms.  
 
Small studies of less than 50 patients have described the use of F-fluorodeoxyglucose 
positron emission tomography (FDG-PET) imaging in the staging of patients with 
locally advanced breast cancer. The detection rates of confirmed distant metastatic 
disease ranged from 8% to 14%, and the rates of false-positive results in the studies 
ranged from 0% to 21%21. FDG-PET is superior to CT in the detection of internal 
mammary and mediastinal lymph node metastasis; however, the impact of the 
increased sensitivity on clinical management and patient outcome is not known22. 
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Currently, there is insufficient evidence to support the routine use of FDG-PET for the 
initial staging evaluation of breast cancer23. 
 
PROGNOSIS 
 
Prognostic factors for locally advanced breast cancer are, in general, similar to those 
for breast cancer at other stages. Tumor size and site of regional lymph node 
metastasis (i.e., axillary, infraclavicular, supraclavicular, or internal mammary), which 
make up the basis of the current staging system, have the greatest impact on disease 
recurrence and survival 24. There is a strong association between survival rates and 
number of involved nodes, with one study reporting 5-year survival of 73% for 
patients with metastases in one to three lymph nodes, compared with 46% for patients 
with metastases in four or more nodes 25. The vast majority of these patients did not 
receive chemotherapy. Increasing size of the primary tumor also has prognostic 
significance for patients with breast cancer, even in women with tumors larger than 5 
cm in diameter26. Data from the San Antonio database indicate that patients with 
tumors measuring 5 to 6 cm in diameter have a 5-year disease-free survival rate of 
72%, compared with 57% for patients with tumors larger than 6 cm. Tumor 
expression of ER and/or PR is generally considered a weak favorable prognostic 
factor and is highly predictive for response to hormonal treatment. HER2/ neu-
positive versus HER2/neu-negative status has been associated with a poorer prognosis 
in patients with lymph node–positive disease in the majority of studies27. HER2/ neu 
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is also a strong predictor of response to trastuzumab and anthracycline-based 
chemotherapy28. 
 
In the recently updated American Society of Clinical Oncology (ASCO) guidelines for 
the use of tumor markers in breast cancer, the routine evaluation of novel tumor 
markers such as urokinase plasminogen activator (UPA) and plasminogen activator 
inhibitor (PAI)-1, p53, cathepsin, cyclin E, and the Oncotype DX assay were not 
recommended for patients with lymph node–positive breast cancer. More recently, 
advances in microarray technology have allowed for further classification of breast 
tumors based on the expression of genes that correlate with survival and response to 
chemotherapy. In a cohort of 51 patients with locally advanced breast cancer (T3–T4 
and/or N2 tumors) treated uniformly with doxorubicin chemotherapy, there was a 
significant decrease in the prognosis of patients with tumors classified as basal type 
compared with those classified as luminal type29.Molecular classification of both 
lymph node–positive and lymph node–negative breast cancers using a 70-gene 
expression signature was more accurate than standard criteria such as the National 
Institutes of Health (NIH) Consensus and the St. Gallen criteria in predicting patients 
at high risk for recurrence30.Prospective randomized trials are currently underway to 
evaluate the clinical utility of molecular profiling of breast tumors for prognosis and 
prediction of response to hormonal therapy and chemotherapy. 
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EVOLUTION OF LOCAL THERAPY 
 
Historically, patients with locally advanced disease have been treated with radical 
mastectomy if technically possible. In 1943 Haagensen and Stout 13, two surgeons at 
Memorial Hospital in New York, published the results of surgical treatment in 1040 
patients with breast cancer. They identified eight factors that were associated with 
uniform recurrence: distant metastases, inflammatory carcinoma, supraclavicular 
lymph node involvement, edema of the arm, satellite breast skin nodules, intercostals 
or parasternal nodules, extensive edema of skin over the breast, and carcinoma that 
developed during pregnancy or lactation. Haagensen and Stout concluded that any of 
these signs of advanced disease made a tumor “categorically inoperable.” These 
authors also defined five “grave signs”: skin ulceration, edema of limited extent, 
fixation of tumor to the chest wall, axillary lymph nodes greater than 2.5 cm in 
diameter, and fixed axillary lymph nodes. Any patient who had two or more of these 
signs was also considered to have inoperable disease because, in their series, only one 
of such patients was without disease recurrence at 5 years. 
 
 Thus, the authors recommended that surgery not be performed in patients with locally 
advanced disease who had the worst prognoses13.The overall survival rates for patients 
with locally advanced breast cancer treated with surgical therapy alone remained poor. 
Failure of mastectomy alone to produce good survival rates prompted the use of 
primary radiation therapy for locally advanced tumors, especially those that were 
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considered inoperable. The results of multiple series indicated however that radiation 
alone was inadequate for patients with locally advanced disease31. 
 
For patients who are treated with primary radiation therapy, a high dose of radiation 
was deemed necessary to optimize local control 32.However, the high doses of 
radiation necessary to achieve local control were associated with considerable 
complications, including chest wall fibrosis, brachial plexopathy, lymphedema, skin 
ulceration, and rib necrosis33. Combined modality therapy that includes surgery and 
radiation therapy in patients with locally advanced disease has resulted in local control 
rates of 70% to 86%34. Patients with locally advanced disease benefit from local 
therapy, but the inadequate cure rates associated with such an approach clearly 
necessitate that systemic therapy be used. 
 
 
COMBINED MODALITY TREATMENT 
 
A combined modality approach that incorporates radiotherapy, surgery, or both; 
systemic therapy that includes chemotherapy and targeted agents such as trastuzumab; 
and hormonal therapy when indicated is currently widely used for the management of 
patients with locally advanced disease. This multimodality approach requires careful 
planning and coordination between the surgeon, medical oncologist, radiation 
oncologist, and diagnostic specialist but offers the optimal chances of patient cure. 
 
The additional benefit of chemotherapy to surgery and radiation was demonstrated in 
a randomized study of 120 patients with operable stage III breast cancer who were 
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randomized after modified radical mastectomy to receive radiation therapy alone; 
vincristine, doxorubicin (Adriamycin), and cyclophosphamide (VAC) chemotherapy 
alone; or radiotherapy and VAC chemotherapy. The disease-free survival was better 
with combined modality of radiation and chemotherapy than with surgery alone (P < 
0.001), and the 3-year overall survival rates were 57% for patients who received 
radiation therapy alone, 72% for those who received chemotherapy alone, and 90% for 
those who received both chemotherapy and radiation therapy (P < 0.01)35. These early 
findings supporting a role for adjuvant chemotherapy were confirmed by data from the 
Early Breast Cancer 2005 Trialists’ Collaborative Group in their meta-analysis of 
worldwide experience with adjuvant chemotherapy versus no adjuvant chemotherapy 
in randomized clinical trials of approximately 150,000 women. These data 
demonstrated that adjuvant polychemotherapy produced highly significant reductions 
in mortality at 15 years of follow-up in women with node-positive breast cancer, and 
survival was better with anthracycline-based regimens than with regimens based on 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy36. 
 
Neoadjuvant chemotherapy is now preferred for patients with locally advanced breast 
cancer because it can downstage tumors and thus increase the rate of breast-
conserving surgery. In cases of more advanced disease, neoadjuvant chemotherapy 
can render inoperable tumors resectable. Equivalent overall survival has been shown 
for patients who receive neoadjuvant versus adjuvant therapy37. The National Surgical 
Adjuvant Breast and Bowel Project (NSABP) B-18 study involved 1523 women with 
T1–T3, N0–N1, and M0 operable breast cancer who were randomized to receive 
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either four cycles of doxorubicin plus cyclophosphamide given in the neoadjuvant 
setting or four cycles of the same regimen given as adjuvant therapy. At 16 years of 
follow-up, comparison of the neoadjuvant and adjuvant arms revealed no differences 
in the 5-, 8-, and 16-year rates of disease-free survival. There was a trend in favor of 
neoadjuvant chemotherapy compared with adjuvant chemotherapy for disease-free 
and overall survival in women younger than 50 years of age37.  
 
Similar findings were reported by the European Organization for Research and 
Treatment of Cancer (EORTC) Breast Cancer Cooperative Group randomized trial of 
neoadjuvant versus adjuvant chemotherapy in patients with operable breast cancer. In 
this trial, 698 patients with stage T1c–T4b, N0–N1, and M0 operable breast cancer 
received either four cycles of neoadjuvant chemotherapy with fluorouracil, epirubicin, 
and cyclophosphamide (FEC), followed by surgery or surgery followed by four cycles 
of FEC. At a median follow-up of 56 months, there were no significant differences 
between the two arms in overall survival, progression- free survival rates, or time to 
local-regional recurrence.  
 
The optimal regimen, duration, and sequencing of neoadjuvant chemotherapy has not 
yet been determined. However, the National Comprehensive Cancer Network 
(NCCN) guidelines indicate a preference for neoadjuvant regimens that contain both 
an anthracycline and taxane for patients with locally advanced breast cancer given the 
superior outcome of these regimens in the adjuvant setting for patients with lymph 
node–positive disease38. Among patients with HER2/neu-positive tumors, neoadjuvant 
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trastuzumab-, taxane-, and anthracycline- based regimens yield significantly higher 
clinical complete response (cCR) and pathologic complete response (pCR) rates,39 
although follow-up is still needed for long-term assessment of disease-free and overall 
survival. Adjuvant hormonal therapy with tamoxifen for premenopausal women39 or 
aromatase inhibitors for postmenopausal women 41 improves disease-free survival and 
is incorporated into the systemic management of patients with locally advanced breast 
cancer as indicated based on the ER and PR status of the tumor. 
The NCCN guidelines recommend postmastectomy radiation for all patients with 
pathologic confirmation of four or more positive axillary lymph nodes, T3 tumors, or 
clinical stage III disease 42. However, a consensus has not been reached regarding the 
efficacy of postmastectomy radiation in patients treated with neoadjuvant 
chemotherapy. 
 
 The ASCO guidelines state that there are “insufficient data” to support a role for 
postmastectomy radiation for patients treated with neoadjuvant chemotherapy43. In a 
retrospective review of 150 patients (48% with stage IIIA or IIIB disease) treated with 
neoadjuvant chemotherapy followed by mastectomy at the M.D. Anderson Cancer 
Center, the 5- and 10-year rates of local-regional recurrence were both 27%. In 
patients with clinical stage III disease at diagnosis, the 5-year local-regional 
recurrence rate was 20%. In patients with clinical stage III disease who attained a 
pCR, the 5-year local-regional recurrence rate remained elevated at 33%. Increased 
pathologic tumor size and number of residual involved lymph nodes were associated 
with higher 5-year rates of local-regional recurrence44. 
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 Data from the NSABP B-18 and NSABP B-27 studies that randomized stage II and 
III patients to receive neoadjuvant or adjuvant chemotherapy prohibited the use of 
postmastectomy radiation, and patients who underwent lumpectomy received breast 
radiation only. In both studies, post-treatment pathologic lymph node involvement 
was a strong predictor of disease-free and overall survival (P < 0.0001)37. 
 
There are no randomized studies evaluating the benefit of postmastectomy radiation in 
patients treated with neoadjuvant chemotherapy. Huang and colleagues compared the 
outcome of 542 patients (73% with stage III disease) enrolled on several neoadjuvant 
chemotherapy trials who received mastectomy and radiation with a cohort of 138 
patients (46% with stage III disease) who received similar treatment but who did not 
receive radiation. Patients who received postmastectomy radiation had a lower 10-
year rate of local-regional recurrence (8%) compared with those who did not receive 
radiation (22%). Radiation also significantly improved the overall and cause-specific 
survival in patients with stage IIIB and IIIC disease and patients with four or more 
residual involved lymph nodes45.It is recommended that patients with baseline tumor 
characteristics that predict an increased risk of local-regional recurrence receive 
postmastectomy radiation after neoadjuvant therapy regardless of clinical response46. 
This clinical practice requires the early involvement of the radiation oncologist in the 
multidisciplinary treatment planning of patients with locally advanced breast cancer.
  
26 
 
Neoadjuvant chemotherapy for the treatment of breast cancer was introduced in the 
1970s for patients with locally advanced disease. The terms neoadjuvant, primary, 
preoperative, and induction are all used to describe systemic chemotherapy given as 
initial therapy. Giving chemotherapy before other treatments has many theoretical 
advantages. Neoadjuvant chemotherapy can result in downstaging of tumors, thus 
increasing the rate of breast-conserving surgery. In cases of more advanced disease, 
neoadjuvant chemotherapy can render inoperable tumors resectable. Other advantages 
of neoadjuvant therapy include the ability to obtain information on tumor response, 
which can be used to study the biologic effects of chemotherapy and determine long-
term disease-free and overall survival47.Although neoadjuvant chemotherapy is 
recommended in the NCCN guidelines for the management of women with locally 
advanced operable or inoperable breast cancer, it can be offered to all patients who 
would otherwise receive adjuvant chemotherapy48. 
 
The NCCN guidelines indicate a preference for neoadjuvant regimens that contain 
both anthracycline and taxane for patients with locally advanced breast cancer.42 
Dieras and colleagues compared neoadjuvant doxorubicin with cyclophosphamide 
(AC) and doxorubicin with paclitaxel (AP), and higher cCR and pCR rates were 
associated with AP (cCR 15%, pCR 16%) than AC chemotherapy (cCR 7%, pCR 
10%). Breast-conserving surgery was more frequent in the AP arm (58%) than the AC 
arm (45%; P value not provided).49 Similar findings of a higher cCR and pCR were 
seen in the Anglo-Celtic Cooperative Oncology Group study that compared the 
combination of doxorubicin with docetaxel (AD) and AC. However, breast-
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conserving surgery rates were equivalent (20%).50 Steger and associates investigated 
whether six cycles of epirubicin and docetaxel (EC) resulted in a higher rate of pCR 
than three cycles of the same regimen in 262 breast cancer patients with stage II and 
III disease. Six cycles of EC compared with three cycles of EC resulted in a higher 
pCR (18.6 vs. 7.7%, respectively, P ¼ 0.0045) and a trend toward a higher rate of 
breast-conserving surgery.51 
 
Several randomized studies have also investigated the sequential administration of 
taxanes following an anthracycline-based regimen and have showed higher rates of 
pCR. In the NSABP B-27 study, which included 2344 patients with stages II and III 
breast cancer, all patients were assigned to receive four cycles of doxorubicin and 
cyclophosphamide (AC) before surgery. Group 1 received no further treatment, group 
2 received sequential neoadjuvant docetaxel for four cycles, and group 3 received 
adjuvant docetaxel for four cycles. Following surgery and radiation for patients who 
underwent lumpectomy, all patients received tamoxifen regardless of age or ER or PR 
status. Eighty-six percent of patients who received neoadjuvant AC alone (groups 1 
and 3) experienced a clinical response compared with 91% of patients who received 
neoadjuvant AC and sequential docetaxel chemotherapy (P < 0.001). The cCR rate 
increased from 40% to 60% with the addition of neoadjuvant docetaxel, and the pCR 
rate increased from 13% to 26%. The improvement in pCR with the addition of 
docetaxel did not translate into an improvement in disease-free or overall survival, 
although relapse-free survival favored the neoadjuvant docetaxel arm.37 
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Similar findings were seen in the German Preoperative Adriamycin Docetaxel study, 
which randomized 904 patients with stage II and III breast cancer to receive four 
cycles of doxorubicin (Adriamycin) and docetaxel (AD) chemotherapy or four cycles 
of AC chemotherapy followed by four cycles of docetaxel. The arm that contained 
sequential administration of docetaxel resulted in a higher pCR (14.3%) compared 
with the combination arm (7%; P < 0.001).52 The sequential administration of taxanes 
also provides benefit for patients who fail to respond to an anthracycline- based 
neoadjuvant regimen. In a study of 167 patients with locally advanced breast cancer, 
responders to four cycles of neoadjuvant cyclophosphamide, vincristine, doxorubicin, 
and prednisolone (CVAP) chemotherapy were randomized to receive either four 
additional cycles of CVAP or four cycles of docetaxel; nonresponders were all treated 
with four cycles of docetaxel. Patients who received docetaxel showed significantly 
higher clinical and pathologic response rates and significantly better 3-year survival 
rates (97% vs. 84%, P ¼ 0.02).53Caution should be taken when comparing the rates of 
cCR and pCR between neoadjuvant studies because of the different criteria used to 
define these outcomes.48 A pCR defined by the complete eradication of invasive 
disease in both the breast and the lymph nodes is a prognostic factor for improved 
disease-free survival, and patients who attain a pCR have been shown to have 
improved overall survival.54 
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NEOADJUVANT TRASTUZUMAB BASED THERAPY 
 
Trastuzumab has been integrated into the neoadjuvant setting in combination with 
chemotherapy for the treatment of patients with locally advanced breast cancer. In the 
majority of studies, tumors were considered HER2/ neu-positive if the 
immunohistochemical (IHC) assay (DAKO) showed 3þ staining or there was gene 
amplification by fluorescent in situ hybridization (FISH). Because of concerns 
regarding the elevated rate of cardiac toxicity 55 associated with the combination of 
anthracyclines and trastuzumab, neoadjuvant studies have focused predominantly on 
combining trastuzumab with taxane-based regimens. Limentani and coworkers 
evaluated the neoadjuvant combination of six cycles of docetaxel and vinorelbine 
given every 2 weeks with weekly trastuzumab for 12 weeks in 31 patients with locally 
advanced breast cancer, and they observed a clinical response rate of 94% and a pCR 
of 39%.56 Burstein and colleagues treated 40 patients with stage II and III breast 
cancer (eight with HER2/neu IHC 2þ) with neoadjuvant paclitaxel every 3 weeks for 
four cycles with 12 weeks of trastuzumab. There was a 75% rate of clinical response 
(84% in patients with HER2/neu IHC 3þ vs. 34% in patients with HER2/neu IHC 2þ) 
and a pCR of 18%.57 Increased pCR rates were also observed in a multicentered study 
of 70 patients with stage II and III operable breast cancer who received docetaxel and 
carboplatin for six cycles with weekly trastuzumab. Clinical response and pCR were 
observed in 95% and 37% of patients, respectively.38 
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 Wenzel and associates conducted a pilot study to determine the feasibility, 
toxicity, and efficacy of the neoadjuvant combination of epirubicin, docetaxel, and 
trastuzumab in patients with early-stage breast cancer. At a median follow-up of 2 
years, there was no significant decline of left ventricular ejection fraction and no 
clinical heart failure.58 The safety profile demonstrated in this pilot study was also 
shown in the neoadjuvant trial by Buzdar and coworkers of 42 patients with T1–3, 
N0–1 and M0 disease who were randomized to receive paclitaxel every 3 weeks for 
four cycles followed by 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) for 
four cycles versus paclitaxel every 3 weeks for four cycles with trastuzumab for 12 
weeks followed by FECfor four cycles with trastuzumab for 12 weeks. The study was 
closed prematurely because of an unequivocal advantage for the arm containing 
trastuzumab. There was a pCR of 26% in the chemotherapy and 60% in the 
trastuzumab arm.37At a median follow-up of 36 months, the disease-free survival was 
85% and 100% for patients in the chemotherapy and trastuzumab arms, respectively, 
and no patient developed clinically apparent cardiac toxicity.59These small studies 
demonstrated promising increased efficacy of trastuzumab-based neoadjuvant 
chemotherapy regimens for patients with HER2/neupositive tumors; however, long-
term follow-up to determine disease-free and overall survival in addition to toxicity is 
needed. 
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NEOADJUVANT HORMONAL THERAPY  
  
The role of neoadjuvant hormonal therapy for patients with ER-positive and/or PR-
positive, large operable, and locally advanced breast cancer has been assessed in 
several studies. Tamoxifen was first investigated as an alternative to surgery in elderly 
patients with large operable tumors with the goal of determining whether surgery 
could be avoided in a selected population of elderly patients.Local failure rates were 
higher in patients treated with tamoxifen alone, but none of the studies showed a 
benefit for surgery in decreasing the development of distant metastatic disease. These 
studies demonstrated that hormonal therapy is an effective alternative for elderly 
women with locally advanced disease who have a limited life expectancy.  
 
Randomized trials have since been conducted comparing tamoxifen with the 
aromatase inhibitors in the neoadjuvant setting. Ellis and colleagues reported a 
randomized trial of tamoxifen versus letrozole in postmenopausal patients with 
hormone receptor–positive tumors who were not candidates for breast-conserving 
surgery. Overall, 60% of patients treated with letrozole responded, and 48% 
underwent successful breast-conserving surgery. In the tamoxifen arm, 41% of 
patients responded, and 36% underwent breast-conserving surgery.60 
 
 In the Immediate Preoperative Anastrozole, Tamoxifen or Combined with Tamoxifen 
(IMPACT) trial, postmenopausal women with ER-positive operable and locally 
advanced potentially operable breast cancer were randomized to receive neoadjuvant 
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tamoxifen, anastrozole, or a combination of the two agents for 3 months. There was 
no significant difference in the approximately 36% clinical response rate among the 
three treatment arms. Patients who received anastrozole alone had a higher rate of 
breast-conserving surgery (44%) compared with patients who received tamoxifen 
alone (31%).61 The Preoperative Arimidex Compared with Tamoxifen (PROACT) 
trial enrolled 451 postmenopausal women with ER-positive and/or PR-positive large 
operable and inoperable breast cancer. Patients could receive concomitant 
chemotherapy, and surgery was planned after 3 months. The overall objective 
response rates were 39.5% with anastrozole versus 35.4% with tamoxifen. In patients 
who received neoadjuvant hormonal therapy alone, 43% and 31% treated with 
anastrozole and tamoxifen, respectively, were able to undergo breast-conserving 
surgery.62 Although randomized studies have established the potential superiority of 
neoadjuvant aromatase inhibitor therapy for clinical response, the pCR rates for 
tamoxifen and the aromatase inhibitors are consistently low across all studies, ranging 
from 1% to 8%. 
 
There are few randomized studies that have compared upfront neoadjuvant 
chemotherapy with neoadjuvant hormonal therapy. In a randomized trial reported by 
Gazet and colleagues, patients with locally advanced breast cancer received either 
neoadjuvant chemotherapy or hormonal therapy. The hormonal therapy consisted of a 
luteinizing hormone–releasing hormone (LHRH) analogue, goserelin, for 
premenopausal women and 4-hydroxyandrostenedione for postmenopausal women. In 
the chemotherapy arm, 27% of patients had a complete response and 27% had a 
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partial response. In contrast, no patients in the hormonal therapy arm had a complete 
response and only 10% had a partial response.63 Semiglazov and associates 
randomized postmenopausal patients with ER-positive and/or PR-positive tumors to 
receive either neoadjuvant anastrozole or exemestane for 3 months or doxorubicin 
with paclitaxel (four 3-week cycles). Clinical objective response rates were 64% in 
both the hormonal therapy and chemotherapy arms. Pathologic response rates were 
3% and 7% (P > 0.05) in the neoadjuvant hormonal therapy and chemotherapy 
treatment arms, respectively.64 
 
ASSESSMENT OF RESPONSE TO NEOADJUVANT 
CHEMOTHERAPY 
 
One advantage of neoadjuvant chemotherapy has been the ability to monitor response 
to chemotherapy so that regimens can be changed in patients who are not responding 
and help them avoid needless toxicity. Accurate assessment of tumor response is 
therefore a critical component of neoadjuvant therapy. Because clinical assessment of 
response to chemotherapy is sometimes inaccurate and subject to substantial 
interobserver variability, the role of imaging modalities such as mammography, 
ultrasonography, and breast MRI has been explored.65-68 Herrada and coworkers 
67found that the combination of physical examination and mammography increased 
the accuracy of the measurement of tumor dimensions. Other authors have found that 
for the measurement of the primary tumor, ultrasonography is more accurate than 
either clinical examination or mammography alone.66 Kuerer and colleagues 69studied 
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the role of physical examination and ultrasonography in assessing axillary lymph node 
status in patients with locally advanced breast cancer treated with neoadjuvant 
chemotherapy. The authors found that axillary sonography was more sensitive than 
physical examination in detecting axillary metastases (62% vs. 45%, P ¼ 0.012). 
Small studies have reported an additional benefit of breast MRI for assessing response 
to neoadjuvant chemotherapy.70-73  
 
Yeh and associates evaluated 41 women with stage II and III breast cancer who 
received neoadjuvant chemotherapy. All underwent physical examination, ultrasound, 
mammography, and breast MRI before and after each cycle of treatment, and the 
agreement rates of clinical response were 32%, 48%, and 55%, respectively, for 
mammography, ultrasound, and breast MRI compared with clinical examination. The 
agreement rates of pathologic response were 19%, 26%, 35%, and 71% for clinical 
examination, mammogram, ultrasound, and MRI, respectively, compared with the 
gold standard, pathologic evaluation.71 A limitation for the routine use of breast MRI 
for evaluating response to neoadjuvant chemotherapy is its high cost. There is also 
evidence that the accuracy of breast MRI for predicting cPR depends on the type of 
neoadjuvant chemotherapy regimen. Higher false-negative rates have been observed 
in HER2/ neu-negative patients, especially in those receiving antiangiogenic agents.74 
Other imaging modalities, such as PET, nuclear medicine sestamibi uptake scans, and 
dynamic contrast-enhanced MRI are being evaluated for a role in assessing response 
to neoadjuvant therapy. 
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PREDICTORS OF RESPONSE TO NEOADJUVANT THERAPY 
 
Multiple studies have evaluated factors that may be predictive of a response to 
neoadjuvant chemotherapy or hormonal therapy. Smaller tumor size, poorly 
differentiated and hormone receptor-negative tumors are significantly more likely to 
respond to neoadjuvant chemotherapy than larger, well-differentiated, and hormone 
receptor–positive tumors.75,76 Triple-negative tumor status (ER-, PR-, and HER2/neu-
negative status) is also a strong predictor for response to neoadjuvant therapy.77In an 
M.D. Anderson Cancer Center report of 1118 patients receiving neoadjuvant 
chemotherapy that included locally advanced and inflammatory breast cancers, 
patients with triple-negative disease had significantly higher rates of pCR (22%) than 
patients without triple-negative disease (11%; P ¼ 0.034).78 In patients receiving 
neoadjuvant hormonal therapy, the degree of ER expression, HER2/neu status and 
Ki67 proliferation index scores have shown correlation with clinical response.60,61 
Studies are underway to identify tumor gene-expression profiles that predict for 
response to neoadjuvant chemotherapy or hormonal therapy. In a study of 89 patients 
with locally advanced breast cancer treated with neoadjuvant paclitaxel and 
doxorubicin, 24 genes that related to ER expression, proliferation, and immune 
regulation obtained using tumor DNA microarrays were associated with pCR.79 Chang 
and coworkers evaluated 24 patients with locally advanced invasive breast cancer 
treated with neoadjuvant docetaxel chemotherapy and showed that differential 
expression of 92 genes correlated with response to treatment (P ¼ 0.001).80 It is 
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anticipated that this type of molecular profiling will become essential for customizing 
therapies for patients with locally advanced breast cancer. 
 
HANDLING OF SURGICAL RESECTION SPECIMENS AFTER 
NEOADJUVANT CHEMOTHERAPY  
 
Before the examination and sampling of the surgical resection specimen it is 
absolutely essential to obtain as many clinical data as possible, including the 
radiologic report. Under ideal conditions mammography X-Rays should be sent to the 
pathologist together with the surgical specimen, or the pathologist should have access 
to the mammograms through the hospital interdepartmental information technology 
system. 
 
 The essential data include: 
• The histologic diagnosis on the pre-treatment core biopsy.  
• Axillary lymph node status.  
• The length of chemotherapy and the drugs that were used.  
• The size and location of the tumor prior and after chemotherapy.  
• Clinical and radiologic impression of the treatment response 
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MASTECTOMY SPECIMEN  
 
The mastectomy specimen should be received fresh with a mark indicating the axillary 
tail. Detailed clinical information including the pretreatment tumor size and location 
and post-treatment radiologic imaging finding are absolutely essential before 
examining the specimen. If lesions are thought to be multiple it is imperative to have 
the mammogram or at least a detailed radiology report describing the mammography 
data. The posterior surface (deep margin) of the mastectomy specimen is inked. The 
specimen is serially sectioned at a 5 mm interval from the posterior surface leaving the 
skin intact.  
The cut surface is examined for evidence of tumor (tumor bed), residual tumor and 
previous biopsy site, especially at the locations corresponding to the radiology report. 
Grossly, the tumor bed appears as a poorly defined fibrotic area or simply fibrotic 
streaks; the residual tumor appears as fleshy nodules or areas. The tumor bed size and 
distance to margins should be measured. If a patient has had an excellent response to 
neoadjuvant chemotherapy, a gross lesion may not be detected, and the specimen may 
be sent to radiology for X-Ray to identify the previous biopsy clip (if was placed 
previously). The sampling method and number of blocks taken vary among 
institutions and are dependent on the size of the specimen and the size of the lesion. In 
general, the previous tumor bed should be sampled extensively; additional or entire 
sampling may be necessary if the initial sections don't show microscopic residual 
tumor. 
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AXILLARY LYMPH NODES  
The axillary lymph node sample may include sentinel lymph node or axillary lymph 
node dissection after neoadjuvant chemotherapy. The specimen is handled the same 
way as for lymph node in the non-neoadjuvant setting. Axillary lymph nodes are 
usually smaller and atrophic therefore more difficult to identify after neoadjuvant 
chemotherapy. 
 
CHEMOTHERAPY INDUCED CHANGES IN BREAST CANCER 
 The neoadjuvant chemotherapy effect is recognized as a fibrous or fibromyxoid area 
containing patchy lymphocytes, histiocytes, and absence of normal breast ducts and 
TDLUs. Hemosiderin laden macrophages and foreign body giant cells are also present 
in the tumor bed representing previous biopsy site. When the tumor bed is extensively 
sampled and no tumor cells are identified, this is termed complete pathologic 
response. If residual cancer cells are present, they may be seen as infiltrating cords 
and nests , or sparse and singly dispersed cells mimicking histiocytes. On the other 
hand, collections of histiocytes may resemble residual tumor cells. 
Immunohistochemical stains with cytokeratin and CD68 will help in differentiating 
tumor cells from histiocytes . Residual tumor nests may show marked retraction 
artifact in the fibrous stroma mimicking lymphovascular invasion; 
immunohistochemical stain for lymphatic channel marker D2-40 may be useful to 
distinguish tissue retraction from lymphatic invasion. Specimens containing residual 
tumor cells are labeled as showing signs of a partial pathologic response. Residual 
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cancer cells surviving chemotherapy may show a spectrum of changes, which are 
evident in the invasive as well as the in-situ component of the tumor. Most common 
chemotherapy effects include nuclear hyperchromasia, nuclear pleomorphism and 
cytoplasmic changes such as hypereosinophilic cytoplasm and vacuolization . The size 
or extent of the residual breast cancer is measured as the largest contiguous focus of 
residual carcinoma or the number of tumor foci encompassing the area of tumor bed. 
The margins of residual tumor (DCIS and invasive carcinoma) should be evaluated 
and distance reported. 
 
CHANGES IN LYMPH NODES 
 Axillary lymph nodes may become small and atrophic after neoadjuvant 
chemotherapy. Microscopically, lymph nodes may show depletion of lymphocytes, 
fibrosis and collections of histiocytes. The latter two features are indications of prior 
metastases that have responded completely to chemotherapy. Efforts should be made 
to identify residual tumor cells in these lymph nodes and report the presence or 
absence of treatment effects 
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ASSESSMENT OF PATHOLOGICAL RESPONSE TO 
NEOADJUVANT CHEMOTHERAPY 
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MATERIALS AND METHODS 
 
STUDY CENTRE: Institute of General Surgery , Madras Medical College and Rajiv 
Gandhi Government General Hospital , Chennai 
 
DURATION OF STUDY:  May 2017- September 2018 
 
STUDY DESIGN: Observational study 
 
SAMPLE SIZE: 30 
 
INCLUSION CRITERIA:  
 
 Age > 18 years 
 
 Locally advanced carcinoma 
 
 Willing for follow up  
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EXCLUSION CRITERIA 
 
 Prior Breast Surgery  
 
 Prior radiotherapy to breast 
 
 Metastatic disease  
 
ETHICS CLEARANCE: Yes 
 
METHODOLOGY  
 
 Patients aged >18 years presenting with malignant breast lump were evaluated.  
 
 Diagnosis confirmed by core needle biopsy and grade and hormonal status 
assessed and metastatic work up done.  
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 Thirty patients who fulfilled the inclusion criteria were chosen and were sent 
for neoadjuvant chemotherapy.(FAC OR FAC+PACLITAXEL REGIMEN)  
 
 Patients were followed up and response of tumor assessed clinically and 
modified radical mastectomy was done. 
 
 Specimen was analyzed for pathological response and observations made. 
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RESULTS 
 
 
 
 
 
 
Majority of the population belonged to the age group of 50-60 (33%) 
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60% of the patients had right sided breast carcinoma 
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Of the 30 patients having locally advanced carcinoma breast 
 73% belonged to stage IIIA 
 
 27% belonged to stage IIIB 
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 Almost half of the patients were ER positive, PR positive and HER2 negative. 
 
 23% of the patients were triple positive. 
 
 Triple negative and her 2 positive patients were of equal distribution (17%). 
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PREVALENCE OF HORMONAL RECEPTOR STATUS 
 
 
 
 
 
 
Percentage of ER and PR positive tumors were 67% each. 
Percentage of HER2 positive tumors were 40%. 
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Postoperative assessment of specimen was done and pathological response graded 
according to Chevalier classification. 
 53% were of grade 4 
 30% were of grade 3 
 13%were of grade 2 
 3% was of grade 1 
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 Only 17% of patient population showed pathological response to NACT 
 
 83% were non responders 
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DISCUSSION 
 
In India, majority of patients present at locally advanced or at metastatic stages at the 
time of diagnosis. According to various studies, majority of carcinoma breast cases in 
the west report in stages I and II of disease, whereas in India 45.7% report in advanced 
stages. This study was aimed to study the response of locally advanced carcinoma 
breast to neoadjuvant chemotherapy. 
 
Majority of the study population were of the age group of 50-60. Studies suggest that 
the disease peaks at 40–50 years in Indian women.81 Trends for 5‐year age distribution 
among different registries showed a peak relative proportion between 45 and 49 years 
in all registries except in north eastern registries.82 
 
60% of the study population had right sided breast carcinoma.This is against the 
studies reporting higher incidence of left sided invasive and in situ lesions by Faidah 
Badru et al though their results weren’t statistically significant.83 
 
73% of the study population belonged to stage IIIA and 27% belonged to stage 
IIIB.Assessment of hormonal status revealed 43% with ER and PR positive and HER2 
negative and 21% of triple positive and 17% of triple negative and ER/PR negative 
but HER2 positive each. Presence of ER and PR in invasive carcinoma correlates 
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positively with survival and is an important prognostic factor. The determination of 
ER, PR and HER-2 in breast cancer has become part of the standard workup.ER and 
PR positive tumors were 67% each and HER 2 was 40%. 
 
 
 
        Image reference –Rashmi Patnayak et al 84 
 
The prevalence of ER and PR positive status was higher in our study when compared 
with previous studies and HER 2 positivity was almost same as the previous studies. 
 
Post MRM specimen assessment and classification of pathological response according 
to Chevalier classification revealed 3% of grade 1, 13% of grade 2, 30% of grade 3 
and 53% of grade 4 responses each. Overall 17% of study population showed 
complete pathological response and 83% were non responders. This is in line with 
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12% response in a Cochrane study 85. Other investigators have shown that a pCR in 
the primary tumor occurs in 3% to 16% of patients with operable breast cancer and 
LABC.85 
 
In an early study, Lippman86 et al reported on the relationship between estrogen 
receptor status and response rate to cytotoxic chemotherapy in the metastatic breast 
cancer setting. They found statistically increased objective response rates to 
chemotherapy in patients with low or absent ER values, compared with patients with 
higher ER values. In the neoadjuvant setting, the finding that ER negative tumors 
were more likely associated with higher response rates than ER-positive tumors has 
been reported by both Bonadonna et al and Mauriac et al85.The higher prevalence of 
ER positivity could account for the lower response rate to neoadjuvant chemotherapy 
in our study. 
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CONCLUSION 
 Locally advanced breast cancer (LABC) occurs relatively infrequently and 
poses a significant clinical challenge. Even with combined-modality therapy and the 
use of novel drugs, long-term disease-free survival is approximately 50%-70%88, 
indicating that the optimal therapeutic approach for these patients has not yet been 
reached. Neo-adjuvant systemic therapy integrated into a multimodality program is 
the established treatment in LABC. The choice of the optimal chemotherapy regimen 
and the duration of treatment have been extensively assessed in induction systemic 
chemotherapy but no consensus has been developed so far. One more issue that was 
subject of extensive debate in NCT is the importance of response to initial 
chemotherapy. This variable is an established key criterion of the early era of 
induction chemotherapy trials. It represents the main advantage of preoperative 
therapy, which is the feasibility to monitor tumor response and to tailor subsequent 
treatment based on response. Nevertheless, no strong correlation of clinical and 
pathologic responses has been demonstrated. It has been established that a pCR in the 
primary tumor is associated with improved disease-free survival and patients without 
axillary lymph node metastases after neoadjuvant chemotherapy have improved 
disease-free survival. Identifying which tumors are most likely to respond to specific 
agents and regimens could significantly improve prognosis. Clinical management of 
LABC could be modified based on advances in our knowledge of cancer biology and 
genomic profiling to a highly effective individualized approach. 
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Identifying which tumors are most likely to respond to specific agents and regimens 
could significantly improve prognosis. Clinical management of LABC could be 
modified based on advances in our knowledge of cancer biology and genomic 
profiling to a highly effective individualized approach. 
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PROFORMA 
Name:                                       Age:  
 
Menstrual Status 
1. Pre chemo status 
 
 Lump size 
 Axillary status  
 Mammogram report –  
 Core needle biopsy report-  
 Staging workup 
 Tumor stage  
 
2. Chemotherapy details 
 
3. Post chemo status 
 
 Lump size - 
 Axillary status –  
 Mammogram report(if any) 
 Tumor stage  
 Post op biopsy report : 
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INFORMATION SHEET 
 
 TITLE: “ASSESSMENT OF PATHOLOGICAL RESPONSE TO 
NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED 
CARCINOMA BREAST” 
Name of Investigator: Dr.Aarthi V.S..   
Name of Participant: 
Purpose of Research: To assess the pathological response to neoadjuvant 
chemotherapy in carcinoma breast 
Study Design: Prospective Observational Study 
Study Procedures: Patient will be subjected to routine investigations, 
mammogram,core needle biopsy and staging workup.patient will be sent for 
neoadjuvant chemotherapy and response will be assessed after mastectomy 
pathologically. 
Possible Risks: No risks to the patient 
Possible benefits 
To patient : A better understanding of their problem so has to devise a plan of 
management which suits their needs. 
To doctor & to other people:  If this study gives positive results, it can help 
determine the role of pathological response in the treatment of patients with LABC. 
This will help in providing better and complete treatment to other patients in future. 
Confidentiality of the information obtained from you: The privacy of the patients 
in the research will be maintained throughout the study. In the event of any 
publication or presentation resulting from the research, no personally identifiable 
information will be shared 
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Can you decide to stop participating in the study: Taking part in this study is 
voluntary. You are free to decide whether to participate in this study or to withdraw at 
any time 
 
How will your decision to not participate in the study affect you: Your decision 
will not result in any loss of benefits to which you are otherwise entitled. 
 
 
 
 
Signature of Investigator          Signature of Participant 
 
Date : 
Place : 
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PATIENT CONSENT FORM 
 
Study Detail : “ASSESSMENT OF PATHOLOGICAL RESPONSE 
TO NEOADJUVANT CHEMOTHERAPY IN 
CARCINOMA BREAST” 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity 
to ask question and all my questions and doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the Ethics 
committee and the regulatory authorities will not need my permission to look at my health 
records, both in respect of current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties or published, unless 
as required under the law. I agree not to restrict the use of any data or results that arise from this 
study. ❏ 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study 
 
❏ 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests 
and to undergo treatment ❏ 
Signature/thumb impression 
Patient’s Name and Address 
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